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INTRODUCT ION
Hypertension (HT) is a primary risk factor for heart
disease, stroke and renal failure, and is one of the most
critical issues regarding human health [1,2]. HT is also
a lifestyle-related disease and dietary modifications are
effective for its management and prevention, i.e. engag-
ing in moderate physical activity; maintaining normal
body weight for adults; limiting alcohol consumption;
reducing sodium intake; and consuming a diet rich in
fruits, vegetables, and low-fat dairy products with a
reduced content of saturated and total fat [2]. Patients
with mild HT [systolic blood pressure (SBP)/diastolic
blood pressure (DBP), 140–159/90–99 mmHg] with no
risk factors and presence of risk factors other than
diabetes are classified into low- and medium-risk groups,
respectively. Lifestyle changes should be the first thera-
peutic measure in low- and medium-risk hypertensive
patients. If SBP and DBP do not decline to levels lower
than 140 and 90 mmHg, respectively, then antihyper-
tensive drug treatments should be started [3].
As an alternative to drug therapy, it is desirable to
change dietary style and use medicinal plant products for
the prevention and treatment of HT and thereby to avoid
the adverse side-effects of organically synthesized drugs
as well as the high cost of drug therapy [4–7]. In this
regard, the use of plants as medicines dates back to the
earliest years of human life. NS is one of the plants
used as a medicinal herb for more than 2000 years,
is considered safe, and has been shown to have
multi-systemic beneficial actions [8] including hypogly-
cemic [9], hypocholesterolemic [10], and antioxidant
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ABSTRACT
Hypertension (HT) is a lifestyle-related disease and dietary modifications are effective
for its management and prevention. We conducted a randomized, double-blind,
placebo-controlled trial to evaluate the efficacy of treatment with an oral Nigella sativa
(NS) seed extract supplement in patients with mild HT. Subjects were randomized
into three groups: a placebo and two test groups that received 100 and 200 mg of NS
extract twice a day. After 8 weeks, systolic blood pressure (SBP) values in both case
groups were found to be significantly reduced when compared with the baseline
values for each group. In addition, the decrease in SBP in the two case groups was
statistically significant relative to the placebo group (P < 0.05–0.01). Meanwhile,
diastolic blood pressure (DBP) values in the case groups were found to be significantly
reduced from the baseline and a significant reduction was also observed in these
groups (P < 0.01) when compared with the placebo group. In addition, extract
administration reduced both SBP and DBP in a dose-dependent manner. Meanwhile,
NS extract caused a significant decline in the level of total and low-density-lipoprotein
(LDL)-cholesterol relative to baseline data. No complications caused by NS were
observed. The results suggest that the daily use of NS seed extract for 2 months may
have a blood pressure-lowering effect in patients with mild HT.
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[11] properties. There is some controversy about the
cardiovascular actions of NS or its active ingredients, as
some investigators reported no effect on blood pressure
in animals [12] or humans [13], whereas others reported
a dose-dependent decrease in the arterial blood pressure
and heart rate in normal [14] or spontaneously hyper-
tensive rats [15]. Therefore, NS may be considered as an
antihypertensive medicinal plant. For this purpose, we
conducted a single-center, randomized, double-blind,
placebo-controlled, parallel-group trial to evaluate the
efficacy of treatment with an oral NS seed extract
supplement in patients with mild HT.
PAT IENTS AND METHODS
Study design
The current study was a randomized, double-blind,
placebo-controlled, dose–response study, conducted for
8 weeks at the Chamran Hospital (Isfahan) in 2005. The
study was conducted in compliance with the Declaration
of Helsinki (1964) and its revised version (2002). The
protocol was reviewed and approved by the Clinical Trial
Ethics Committee of MUI University (Isfahan) before the
start of the study. The nature of the study, the proposal
of the study design, and the potential risks of participa-
tion in the study were fully explained to each volunteer
and written consent was obtained.
Patients
Healthy male volunteers (n = 119), aged 35 to 50 years,
with mild HT (SBP between 140 and 159 mmHg and/or
DBP between 90 and 99 mmHg) [3] were included in
this study. Subjects were excluded if they were heavy
smokers (more than five cigarettes per day), if they had
received antihypertensive and hypolipidemic therapy
or food additives and vitamins, and if they exhibited
abnormal liver function (aspartate aminotransferase
>100 IU/L and/or alanine aminotransferase >100 IU/L),
or abnormal renal function (blood urea nitrogen
>22 mg/dL and/or serum creatinine >1.3 mg/dL).
Drug preparation
Fresh NS seeds were obtained from Tehran (northern
Iran), washed, and dried at room temperature in the
absence of sunlight. The plant was identified by botanists
in the herbarium of Shaheed Beheshti University (Teh-
ran) and the specimen number of the plant was 2005-
173. Boiled extract of the seeds of the plant was prepared
as follows: 10 g of the ground material was boiled with
100 mL of distilled water for 15 min and allowed to cool
at room temperature. The extract was then filtered
through a sterile cotton cloth until a concentrated
residue (0.1 g%) was obtained. The standardized extract
was then encapsulated in 100- and 200-mg packages
and stored at 0 C until being used. The capsules
containing placebo were indistinguishable from those
containing NS regarding their appearance. The main
ingredients of the essential oil of NS were assessed
using high-performance liquid chromatography (HPLC)
(SPD-10AVP; Shimadzu, Kyoto, Japan) with ODS
column by a phytochemical specialist.
Experimental protocol
Based on the blood pressure value measured 14 days
before the trial, subjects were randomly assigned to three
groups, i.e. placebo and 100- and 200-mg test groups.
Table I Adverse side-effects checklist on case report form.
Category Symptom
Cardiovascular Edema
Palpitation
Constitutional symptoms Fatigue
Fever
Hot flush
Lethargy/drowsiness
Sweating
Dermatological symptoms Eruption
Flushing
Pruritus
Rash
Gastrointestinal symptoms Constipation
Diarrhea
Dysgeusia
Epigastric discomfort
Heartburn
Dry mouth
Nausea
Salivary gland change
Stomach discomfort
Vomiting
Neurological symptoms Dizziness
Dysesthesia
Light-headedness
Paresthesia
Vertigo
Chest pain
Headache
Dull headache
Abdominal pain
Pulmonary Cough
Renal/genitourinary Urinary frequency
Complications were checked by physicians’ regular visits.
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The case groups received extract of NS as two capsules
per day containing 100 and/or 200 mg of the drug. At
baseline (day 0) and at week 8, the body weights were
measured, and fasting blood samples were collected after
blood pressure measurement and subjected to hemato-
logical evaluation (white blood cells, red blood cells,
platelets, hematocrit, and hemoglobin) and blood chem-
ical tests [i.e. aspartate aminotransferase, alanine
aminotransferase, alkaline phosphatase, lactate dehy-
drogenase, blood urea nitrogen, serum creatinine, uric
acid, total protein, albumin, total cholesterol, high-
density-lipoprotein (HDL)-cholesterol and low-density-
lipoprotein (LDL)-cholesterol].
Adverse side-effects were checked by physicians’
interview using a case-report form at baseline (day 0),
and at weeks 4 and 8 (Table I). Subjects were also asked
not to change their dietary habits during the study,
particularly with regard to their consumption of fat, salt,
vegetables, and fruits.
Blood pressure measurement
Blood pressure and pulse were measured 14 days before
the trial, at baseline (day 0), and 4 and 8 weeks after the
start of the study under the morning fasting condition
(12 ± 2 h after the last drug ingestion). Three measure-
ments with an interval of 5 min were taken in the right
arm using an automated sphygmomanometer (HEM-
707; Omron Co, Kyoto, Japan) and an appropriate-sized
cuff after at least 10 min of rest in the seated position.
The median of three measurements was taken as the
measured value.
Statistical analysis
All values were expressed as mean ± SEM. The charac-
teristics of groups at baseline were compared by one-way
analysis of variance (ANOVA). The changes in blood
pressures, pulse, and body weight were analyzed using
one-way repeated-measures ANOVA and Tukey–Kramer
post hoc method and their comparison with the baseline
data. A P-value less than 0.05 was considered to indicate
a statistical significance. Statistical analyses were per-
formed using SPSS statistical software (version 9.5).
RESULTS
The main constituents of the essential oil of NS were
cymenen P (41.5%), terpinene G (13%), campholenel a
(9.8%), thujene a (7.8%), pinene b (2.9%), limonene
(2.9%), pinene a (2.2%), carvacrol (2.2%) thymoquinone
(2.1%), and terpinene a (1.7%).
One hundred and nineteen applicants were enrolled
for the study and 11 were excluded based on the
aforementioned exclusion criteria. Thus, a total of 108
subjects were randomized and completed the study. At
baseline, there were no significant differences among
the three groups regarding blood pressure, pulse, age,
weight, body mass index (BMI), and blood components
(Table II). Four subjects failed to ingest the adminis-
tered drug twice and one subject failed to ingest it
for 3–4 days; thus, 103 subjects ingested 100% of the
doses of the medicine. In our study, no complications
Table II Baseline characteristics of randomized subjects.
Placebo
Nigella sativa
100 mg 200 mg P-value
n 33 36 39
Age (years) 43.1 ± 1.4 44.6 ± 1.3 43.7 ± 1.3 0.92
Weight (kg) 73.2 ± 2.3 70.6 ± 2.1 74.7 ± 2.7 0.46
BMI (kg/m2) 24.5 ± 0.7i 23.9 ± 0.8 24.1 ± 0.8 0.86
SBP (mmHg) 148.2 ± 1.2 151.2 ± 1.3 149.5 ± 1.3 0.26
DBP (mmHg) 94.5 ± 0.8 93.2 ± 0.5 95.1 ± 0.8 0.13
Pulse (beats/min) 74.2 ± 1.9 76.2 ± 2.1 73.2 ± 1.8 0.52
White blood cells
(·103/lL)
7.3 ± 0.6 7.1 ± 0.7 6.5 ± 0.6 0.64
Red blood cells
(·106/lL)
4.6 ± 0.09 4.4 ± 0.1 4.3 ± 0.08 0.06
Platelets (·104/lL) 23.2 ± 1.1 25.4 ± 1.6 24.8 ± 1.5 0.55
Hematocrit (%) 43.7 ± 0.9 43.1 ± 1.2 45.8 ± 1.1 0.17
Hemoglobin (g/dL) 14.8 ± 0.18 15.1 ± 0.17 15.4 ± 0.19 0.07
AST (IU/L) 19.7 ± 1.4 20.8 ± 1.7 20.6 ± 1.7 0.89
ALT (IU/L) 25.1 ± 2.8 26.7 ± 3.7 25.3 ± 3.1 0.93
ALP (IU/L) 196.3 ± 20.1 200.1 ± 23.8 211.8 ± 18.7 0.85
LDH (IU/L) 171.5 ± 10.4 165.8 ± 12.3 172 ± 12.5 0.91
Blood urea nitrogen
(mg/dL)
12.4 ± 0.8 11.7 ± 0.4 12.3 ± 0.7 0.71
Uric acid (mg/dL) 6.1 ± 0.3 6.2 ± 0.2 5.7 ± 0.3 0.37
Serum creatinine
(mg/dL)
0.7 ± 0.04 0.8 ± 0.03 0.8 ± 0.04 0.10
Total protein (g/dL) 6.9 ± 0.2 6.8 ± 0.1 7.1 ± 0.2 0.44
Albumin (g/dL) 4.7 ± 0.1 5.1 ± 0.2 5.2 ± 0.2 0.12
Triglyceride (mg/dL) 121.2 ± 10.3 127.9 ± 10.7 118 ± 9.7 0.77
Total cholesterol
(mg/dL)
189.7 ± 8.7 201.2 ± 9.1 200.7 ± 8.2 0.58
HDL cholesterol
(mg/dL)
47.2 ± 2.9 51.8 ± 3.4 52.7 ± 3.1 0.43
LDL cholesterol
(mg/dL)
123.5 ± 5.4 128.2 ± 6.1 127.7 ± 6.8 0.78
BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine
aminotransferase; ALP, alkaline phosphatase; LDH, lactate dehydrogenase;
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Values are expressed as mean ± SEM.
One-way ANOVA statistical analysis was used.
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in the test or placebo groups were observed on clinical
and physical examination according to defined criteria.
The SBPs of test groups (i.e. NS 100 and NS 200)
were significantly lower than the baseline level (P =
0.04 and 0.009 after 4 weeks; P = 0.03 and 0.008
after 8 weeks of NS administration, respectively).
Meanwhile, no significant change in SBP was observed
in placebo group when compared with baseline values
(Figure 1). The DBP of the placebo group was not
significantly changed after 4 and 8 weeks (P = 0.31
and 0.22, respectively) when compared with baseline,
whereas those of the test groups showed significant
decreases (P = 0.008 and 0.007 for NS 100 and NS
200, respectively) when compared with baseline data
(Figure 1).
No significant changes in body weight or pulse from
baseline were observed in the two test groups or placebo
group or among the two test groups (Table III). Regard-
ing serum lipids, there was a significant reduction in
total (P < 0.05–0.01) and LDL-cholesterol (P < 0.01)
after 8 weeks of NS administration in test groups when
compared with baseline data. There was also no such
change in the placebo group (Table III).
DISCUSS ION
In the present study, administration of NS seed extract
for 8 weeks reduced SBP and DBP in a dose-dependent
manner and lowered the levels of total and LDL-
cholesterol in patients with mild HT. Research reports
indicate a variety of effective alternative therapies for
alleviating high blood pressure including diet, exercise,
herbs, and so forth. We particularly selected nonsmok-
ing, recently diagnosed patients with mild HT, receiving
no antihypertensive or lipid-lowering pharmaceutical
therapy, with no significant cardiovascular risk factors
other than HT. Patients who reported taking vitamins
and other food additives were also excluded from the
Figure 1 Mean (±SEM) changes in SBP and DBP from baseline
after 4 and 8 weeks of administration of NS extract. SBP, systolic
blood pressure; DBP, diastolic blood pressure. *P < 0.05,
**P < 0.01 when compared with the placebo data (one-way
ANOVA).
Table III Characteristics of randomized subjects after 8 weeks.
Placebo
Nigella sativa
100 mg 200 mg P-value
n 33 36 39
Weight (kg) 72.6 ± 2.4 71.7 ± 2.5 73.2 ± 2.4 0.9
BMI (kg/m2) 24.7 ± 0.8 22.7 ± 0.7 23.5 ± 0.8 0.21
Pulse (beats/min) 75.2 ± 2.1 74.1 ± 1.9 72.8 ± 2.1 0.72
White blood cells
(·103/lL)
7.4 ± 0.7 7.2 ± 0.7 6.7 ± 0.5 0.71
Red blood cells
(·106/lL)
4.6 ± 0.09 4.4 ± 0.1 4.3 ± 0.08 0.06
Platelets (·104/lL) 22.8 ± 1.2 24.1 ± 1.8 23.7 ± 1.4 0.82
Hematocrit (%) 42.8 ± 1.1 42.7 ± 1.3 44.2 ± 1.3 0.62
Hemoglobin (g/dL) 15.1 ± 0.18 15.3 ± 0.17 15.3 ± 0.14 0.61
AST (IU/L) 18.6 ± 1.5 21.7 ± 1.5 21.3 ± 1.9 0.38
ALT (IU/L) 24.2 ± 2.2 25.3 ± 2.7 23.9 ± 2.7 0.92
ALP (IU/L) 191.7 ± 18.9 187.2 ± 17.8 183.2 ± 20.1 0.95
LDH (IU/L) 171.8 ± 11.3 161.4 ± 12.7 165.2 ± 11.9 0.83
Blood urea nitrogen
(mg/dL)
11.5 ± 0.5 11.4 ± 0.7 11.6 ± 0.7 0.97
Uric acid (mg/dL) 6.3 ± 0.3 6.3 ± 0.2 6.2 ± 0.2 0.94
Serum creatinine
(mg/dL)
0.8 ± 0.03 0.7 ± 0.03 0.8 ± 0.03 0.03
Total protein (g/dL) 6.6 ± 0.3 6.1 ± 0.2 6.8 ± 0.2 0.09
Albumin (g/dL) 4.1 ± 0.2 5.3 ± 0.2 4.7 ± 0.1 0.0001
Triglyceride (mg/dL) 124.4 ± 10.7 106.7 ± 11.4 97.4 ± 11.2 0.23
Total cholesterol
(mg/dL)
191.5 ± 12.8 171.3 ± 11.9* 167.1 ± 9.1** 0.27
HDL cholesterol
(mg/dL)
50.3 ± 3.3 50.8 ± 3.7 48.2 ± 2.9 0.83
LDL cholesterol
(mg/dL)
121.5 ± 5.8 104.1 ± 6** 101.6 ± 6.1** 0.04
BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine
aminotransferase; ALP, alkaline phosphatase; LDH, lactate dehydrogenase;
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Values are expressed as mean ± SEM.
*P < 0.05, **P < 0.01 when compared with baseline data.
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trial, avoiding the potential bias arising from recruiting
participants who are more health conscious than
average. The reduction of blood pressure observed in
our study was accompanied by significant changes in
plasma concentrations of total and LDL-cholesterol.
Participants were strictly advised and repeatedly
reminded to maintain their current diet and lifestyle.
Thus, our results are unlikely to be attributed to lipid-
or weight-lowering regimens, dietary changes, or
enhanced physical activity. Although we did not mea-
sure indices of antioxidant defense system and lipid
peroxidation, our assumption is that the reduction in
blood pressure observed in our study was in part due to
the antioxidant activity of the NS extract. The essential
oil of NS seed has antioxidant property that makes it
useful for treating cardiovascular disorders [16–18].
Some researchers have demonstrated a link between the
administration of antioxidants or their respective plasma
levels and the development of HT, atherosclerosis, and
cerebral stroke [19–23]. Our results are consistent with
those examining the effects of vitamins, natural prod-
ucts, or dietary modifications on cardiovascular mor-
bidity, blood pressure, and antioxidant activity [24–26].
In a clinical trial, an increase in consumption of dietary
fruits and vegetables, for an 8-week period reduced SBP
and DBP by nearly 2.8 and 1.1 mmHg, respectively,
more than those receiving control diet [27]. In the
present study, NS seed extract capsules were used. In
these capsules, concentrations of various bioactive
substances were known and standardized, providing a
standard intervention for all subjects. Standardization of
treatment enables researchers to better monitor patients’
compliance to therapy and establish more accurate
dose–response relations. Ease of administration and lack
of side-effects are some of the main characteristics of
natural products such as those used in this study. It is a
well-known fact that lack of compliance, in part due to
side-effects of antihypertensive drug therapy, is an
important cause of treatment failure in hypertensive
patients [28]. The positive results in our pilot trial are
encouraging. However, our relatively small study pop-
ulation comprised low-risk patients with mild HT who
were naive to drug therapy. The course of therapy in
our study was relatively short, and it is not clear
whether the beneficial effect of NS extract will persist
with prolonged administration. The treatment in our
trial was a primary therapeutic intervention and it is
reasonable to assume that these low-risk patients who
have only minor or no vascular damage will be more
responsive to the intervention than patients with
moderate to severe HT and with more advanced
vascular disease and on multiple drug therapy. Reduc-
tion in blood pressure from mild HT range to high
normal range, such as achieved in our pilot study, is
clinically considerable. Maintaining patients in normo-
tensive state and preventing their progression to higher-
grade HT may postpone or even eliminate the need for
an antihypertensive drug therapy. Studies with larger
and more diverse populations examining the antihyper-
tensive effect for longer periods are warranted to
establish the role of this extract as an antihypertensive
agent. This study was also limited by the lack of
availability of measures of endothelial function and
oxidative stress in the studied groups. In addition, self-
reported data for medication use, exercise, and diet
information may not be as precise as expected.
In this study, a significant reduction in total choles-
terol and LDL-cholesterol was also observed following
NS consumption that may be useful in the long term to
lower risk factors of cardiovascular disorders. It has
previously been reported that hypertensive patients are
likely to benefit from therapeutic interventions targeted
at other modifiable risk factors. In particular, the high
prevalence of coexisting HT and dyslipidemia suggests
that many hypertensive patients might benefit from lipid-
lowering therapy. This implies that a combined approach
to reducing blood pressure and cholesterol could be twice
as beneficial as targeting just one of these risk factors
[29,30]. To conclude, this study demonstrated that the
daily intake of NS seed extract could reduce DBP and SBP
that may help prevent stroke and coronary heart disease
in hypertensive subjects.
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